Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa neoadjuvant phase II trial in resectable untreated head and neck squamous cell carcinoma
2019-004052-11Phase 2Completed
- Sponsor
- Unicancer
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by Unicancer. Primary endpoint: Pathological response rate. Started Mar 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-004052-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004052-11.